PNPLA3 as a genetic determinant of risk for and severity of non-alcoholic fatty liver disease spectrum

Journal of Clinical and Translational Hepatology

Volumn 4, Issue 3, 2016, Pages 175-191

  Salameh, Habeeb ^a   Hanayneh, Muhannad Al ^a   Masadeh, Maen ^b   Naseemuddin, Mohammed ^c   Matin, Tasnia ^c   Erwin, Angelika ^d   Singal, Ashwani K ^e  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c University of Alabama at Birmingham   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e University of Alabama at Birmingham   (United States)

Author keywords

Non alcoholic liver disease; PNPLA3; Polymorphisms; Rs738409 C>G

Indexed keywords

EID: 85015038477     PISSN: 22250719     EISSN: 23108819     Source Type: Journal    
DOI: 10.14218/JCTH.2016.00009     Document Type: Article

References (81)

1. Singal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 2013;95:755–760. doi: 10.1097/TP.0b013e31827afb3a.
2. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011;141:1249–1253. doi: 10.1053/j. gastro.2011.06.061.
3. Kotronen A, Johansson LE, Johansson LM, Roos C, Westerbacka J, Hamsten A, et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009;52:1056–1060. doi: 10. 1007/s00125-009-1285-z.
4. Salameh H, Raff E, Erwin A, Seth D, Nischalke HD, Falleti E, et al. PNPLA3 gene polymorphism is associated with predisposition to and severity of alcoholic liver disease. Am J Gastroenterol 2015;110:846–856. doi: 10.1038/ajg.2015.137.
5. Kienesberger PC, Oberer M, Lass A, Zechner R. Mammalian patatin domain containing proteins: a family with diverse lipolytic activities involved in multi-ple biological functions. J Lipid Res 2009;50 Suppl:S63–S68. doi: 10.1194/jlr.R800082-JLR200.
6. Kershaw EE, Hamm JK, Verhagen LA, Peroni O, Katic M, Flier JS. Adipose triglyceride lipase: function, regulation by insulin, and comparison with adiponutrin. Diabetes 2006;55:148–157. doi: 10.2337/diabetes.55.01.06.db05-0982.
7. Day CP. From fat to inflammation. Gastroenterology 2006;130:207–210. doi: 10.1053/j.gastro.2005.11.017.
8. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011;53:1883–1894. doi: 10.1002/hep.24283.
9. Xu R, Tao A, Zhang S, Deng Y, Chen G. Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis. Sci Rep 2015; 5:9284. doi: 10.1038/srep09284.
10. Zhang L, You W, Zhang H, Peng R, Zhu Q, Yao A, et al. PNPLA3 polymor-phisms (rs738409) and non-alcoholic fatty liver disease risk and related phe-notypes: a meta-analysis. J Gastroenterol Hepatol 2015;30:821–829. doi: 10.1111/jgh.12889.
11. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008–2012. doi: 10.1001/jama.283.15.2008.
12. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford. asp.
13. Ungaro R, Bernstein CN, Gearry R, Hviid A, Kolho KL, Kronman MP, et al. Antibiotics associated with increased risk of new-onset Crohn’s disease but not ulcerative colitis: a meta-analysis. Am J Gastroenterol 2014;109:1728– 1738. doi: 10.1038/ajg.2014.246.
14. Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J. How should we use information about HWE in the meta-analyses of genetic association studies? Int J Epidemiol 2008;37:136–146. doi: 10.1093/ije/dym234.
15. Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 2009;169:505–514. doi: 10.1093/aje/kwn359.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–188. doi: 10.1016/0197-2456(86)90046-2.
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–560. doi: 10.1136/bmj.327.7414.557.
18. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heter-ogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG, eds, (ed.). Systematic reviews in health care: meta-analysis in context, 2nd edition. London: BMJ Books, 2005, p.285–312.
19. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–1101. doi: 10.2307/2533446.
20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–634. doi: 10. 1136/bmj.315.7109.629.
21. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455–463. doi: 10.1111/j.0006-341X.2000.00455.x.
22. Available at: http://finzi.psych.upenn.edu/library/metafor/html/trimfill.html.
23. Hamza S, Petit JM, Masson D, Jooste V, Binquet C, Sgro C, et al. PNPLA3 rs738409 GG homozygote status is associated with increased risk of hepa-tocellular carcinoma in cirrhotic patients. J Hepatol 2012;56:S281–S282. doi: 10.1016/S0168-8278(12)60725-9.
24. Way M, McQuillin A, Gurling HMD, Morgan MY. The PNPLA3 I148M mutation significantly increases the risk of developing alcohol-related cirrhosis in alcohol-dependent individuals. J Hepatol 2013;58:S563–S564. doi: 10. 1016/S0168-8278(13)61403-8.
25. Dutta AK. Genetic factors affecting susceptibility to alcoholic liver disease in an Indian population. Ann Hepatol 2013;12:901–907.
26. Nguyen-Khac E, Houchi H, Dreher ML, Herpe YE, Naassila M. Is PNPLA3 poly-morphism involved in severe acute alcoholic hepatitis. Hepatology 2011;54: 976A.
27. Bhatt SP, Nigam P, Misra A, Guleria R, Pandey RM, Pasha MA. Genetic variation in the patatin-like phospholipase domain-containing protein-3 (PNPLA-3) gene in Asian Indians with nonalcoholic fatty liver disease. Metab Syndr Relat Disord 2013;11:329–335. doi: 10.1089/met.2012.0064.
28. Burza MA, Pirazzi C, Maglio C, Sjöholm K, Mancina RM, Svensson PA, et al. PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. Dig Liver Dis 2012;44:1037–1041. doi: 10. 1016/j.dld.2012.05.006.
29. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461–1465. doi: 10.1038/ng.257.
30. Santoro N, Kursawe R, D’Adamo E, Dykas DJ, Zhang CK, Bale AE, et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 2010;52:1281–1290. doi: 10.1002/hep.23832.
31. Kantartzis K, Peter A, Machicao F, Machann J, Wagner S, Königsrainer I, et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 2009;58:2616– 2623. doi: 10.2337/db09-0279.
32. Sookoian S, Castaño GO, Burgueño AL, Gianotti TF, Rosselli MS, Pirola CJ. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009;50:2111–2116. doi: 10.1194/jlr.P900013-JLR200.
33. Petit JM, Guiu B, Masson D, Duvillard L, Jooste V, Buffier P, et al. Specifically PNPLA3-mediated accumulation of liver fat in obese patients with type 2 diabetes. J Clin Endocrinol Metab 2010;95:E430–E436. doi: 10.1210/jc. 2010-0814.
34. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M poly-poly-morphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1209–1217. doi: 10.1002/hep.23622. morphism
35. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ, NASH CRN. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010;52:894–903. doi: 10.1002/hep.23759.
36. Goran MI, Walker R, Le KA, Mahurkar S, Vikman S, Davis JN, et al. Effects of PNPLA3 on liver fat and metabolic profile in Hispanic children and adoles-cents. Diabetes 2010;59:3127–3130. doi: 10.2337/db10-0554.
37. Speliotes EK, Butler JL, Palmer CD, Voight BF, GIANT Consortium, MIGen Consortium, et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010;52:904–912. doi: 10.1002/hep.23768.
38. Valenti L, Alisi A, Galmozzi E, Bartuli A, Del Menico B, Alterio A, et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 2010;52:1274–1280. doi: 10.1002/hep.23823.
39. Wang CW, Lin HY, Shin SJ, Yu ML, Lin ZY, Dai CY, et al. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. Liver Int 2011;31:1326– 1331. doi: 10.1111/j.1478-3231.2011.02526.x.
40. Hotta K, Yoneda M, Hyogo H, Ochi H, Mizusawa S, Ueno T, et al. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med Genet 2010;11:172. doi: 10.1186/1471-2350-11-172.
41. Lin YC, Chang PF, Hu FC, Yang WS, Chang MH, Ni YH. A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children. J Pediatr 2011;158:740–744. doi: 10.1016/j.jpeds.2010.11.016.
42. Peng XE, Wu YL, Lin SW, Lu QQ, Hu ZJ, Lin X. Genetic variants in PNPLA3 and risk of non-alcoholic fatty liver disease in a Han Chinese population. PLoS One 2012;7:e50256. doi: 10.1371/journal.pone.0050256.
43. Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One 2012;7:e38322. doi: 10.1371/journal.pone.0038322.
44. Petta S, Grimaudo S, Cammà C, Cabibi D, Di Marco V, Licata G, et al. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. J Hepatol 2012;56:1356–1362. doi: 10. 1016/j.jhep.2012.01.007.
45. Zain SM, Mohamed R, Mahadeva S, Cheah PL, Rampal S, Basu RC, et al. A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease. Hum Genet 2012;131:1145– 1152. doi: 10.1007/s00439-012-1141-y.
46. Li Y, Xing C, Cohen JC, Hobbs HH. Genetic variant in PNPLA3 is associated with nonalcoholic fatty liver disease in China. Hepatology 2012;55:327–328. doi: 10.1002/hep.24659.
47. Kitamoto T, Kitamoto A, Yoneda M, Hyogo H, Ochi H, Nakamura T, et al. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet 2013;132:783–792. doi: 10.1007/s00439-013-1294-3.
48. Islek EE, Sazci A, Ozel MD, Aygun C. Genetic variants in the PNPLA3 gene are associated with nonalcoholic steatohepatitis. Genet Test Mol Biomarkers 2014;18:489–496. doi: 10.1089/gtmb.2014.0019.
49. Guichelaar MM, Gawrieh S, Olivier M, Viker K, Krishnan A, Sanderson S, et al. Interactions of allelic variance of PNPLA3 with nongenetic factors in predicting nonalcoholic steatohepatitis and nonhepatic complications of severe obesity. Obesity (Silver Spring) 2013;21:1935–1941. doi: 10.1002/oby.20327.
50. Tai CM, Huang CK, Tu HP, Hwang JC, Chang CY, Yu ML. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease. Surg Obes Relat Dis 2015;11:888–894. doi: 10.1016/j.soard.2014.07.016.
51. Kanth VV, Sasikala M, Rao PN, Steffie Avanthi U, Rao KR, Nageshwar Reddy D. Pooled genetic analysis in ultrasound measured non-alcoholic fatty liver disease in Indian subjects: A pilot study. World J Hepatol 2014;6:435–442. doi: 10.4254/wjh.v6.i6.435.
52. Lin YC, Chang PF, Chang MH, Ni YH. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals. Am J Clin Nutr 2014;99:869–874. doi: 10.3945/ajcn.113.079749.
53. Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, Dufour JF, et al. Carriage of the PNPLA3 rs738409 C>G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 2014;61:75–81. doi: 10.1016/j.jhep.2014.02.030.
54. Verrijken A, Beckers S, Francque S, Hilden H, Caron S, Zegers D, et al. A gene variant of PNPLA3, but not of APOC3, is associated with histological param-eters of NAFLD in an obese population. Obesity (Silver Spring) 2013;21: 2138–2145. doi: 10.1002/oby.20366.
55. Wagenknecht LE, Palmer ND, Bowden DW, Rotter JI, Norris JM, Ziegler J, et al. Association of PNPLA3 with non-alcoholic fatty liver disease in a minority cohort: the Insulin Resistance Atherosclerosis Family Study. Liver Int 2011;31:412–416. doi: 10.1111/j.1478-3231.2010.02444.x.
56. Akuta N, Kawamura Y, Arase Y, Suzuki F, Sezaki H, Hosaka T, et al. Relationships between genetic variations of PNPLA3, TM6SF2 and histological features of nonalcoholic fatty liver disease in Japan. Gut Liver 2016;10:437–445. doi: 10.5009/gnl15163.
57. Baulande S, Lasnier F, Lucas M, Pairault J. Adiponutrin, a transmembrane protein corresponding to a novel dietary-and obesity-linked mRNA specifically expressed in the adipose lineage. J Biol Chem 2001;276:33336–33344. doi: 10.1074/jbc.M105193200.
58. Wilson PA, Gardner SD, Lambie NM, Commans SA, Crowther DJ. Character-ization of the human patatin-like phospholipase family. J Lipid Res 2006;47: 1940–1949. doi: 10.1194/jlr.M600185-JLR200.
59. He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010;285:6706–6715. doi: 10.1074/jbc. M109.064501.
60. Chamoun Z, Vacca F, Parton RG, Gruenberg J. PNPLA3/adiponutrin functions in lipid droplet formation. Biol Cell 2013;105:219–233. doi: 10.1111/boc. 201200036.
61. Paré G, Ridker PM, Rose L, Barbalic M, Dupuis J, Dehghan A, et al. Genome-wide association analysis of soluble ICAM-1 concentration reveals novel associations at the NFKBIK, PNPLA3, RELA, and SH2B3 loci. PLoS Genet 2011;7:e1001374. doi: 10.1371/journal.pgen.1001374.
62. Qu Z, Wu M, Xie T. Expression of ICAM-1 mRNA in HCC using in situ hybrid-ization technique. Zhonghua Bing Li Xue Za Zhi 1997;26:82–84.
63. Roland CL, Harken AH, Sarr MG, Barnett CC Jr. ICAM-1 expression deter-mines malignant potential of cancer. Surgery 2007;141:705–707. doi: 10. 1016/j.surg.2007.01.016.
64. Trépo E, Nahon P, Bontempi G, Valenti L, Falleti E, Nischalke HD, et al. Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology 2014;59:2170–2177. doi: 10.1002/hep.26767.
65. Edmondson HA, Peters RL, Frankel HH, Borowsky S. The early stage of liver injury in the alcoholic. Medicine (Baltimore) 1967;46:119–129. doi: 10.1097/00005792-196703000-00006.
66. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology 1997;25:108–111. doi: 10. 1002/hep.510250120.
67. Crabb DW. Pathogenesis of alcoholic liver disease: newer mechanisms of injury. Keio J Med 1999;48:184–188. doi: 10.2302/kjm.48.184.
68. Thornton A, Lee P. Publication bias in meta-analysis: its causes and conse-quences. J Clin Epidemiol 2000;53:207–216. doi: 10.1016/S0895-4356(99) 00161-4.
69. Bedossa P. Histological assessment of NAFLD. Dig Dis Sci 2016;61:1348– 1355. doi: 10.1007/s10620-016-4062-0.
70. Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012;56:1751–1759. doi: 10.1002/hep.25889.
71. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–1321. doi: 10.1002/hep. 20701.
72. Baclig MO, Lozano-Kühne JP, Mapua CA, Gopez-Cervantes J, Natividad FF. Genetic variation I148M in patatin-like phospholipase 3 gene and risk of nonalcoholic fatty liver disease among Filipinos. Int J Clin Exp Med 2014;7: 2129–2136.
73. Lee SS, Byoun YS, Jeong SH, Woo BH, Jang ES, Kim JW, et al. Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea. Dig Dis Sci 2014;59:2967–2974. doi: 10.1007/s10620-014-3279-z.
74. Park JH, Cho B, Kwon H, Prilutsky D, Yun JM, Choi HC, et al. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease. Liver Int 2015;35:2537–2546. doi: 10.1111/liv.12909.
75. Wei JL, Leung JC, Loong TC, Wong GL, Yeung DK, Chan RS, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol 2015;110:1306–1314; quiz 1315. doi: 10.1038/ajg.2015.235.
76. Xia MF, Ling Y, Bian H, Lin HD, Yan HM, Chang XX, et al. I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders. Aliment Pharmacol Ther 2016; 43:631–642. doi: 10.1111/apt.13521.
77. Oniki K, Saruwatari J, Izuka T, Kajiwara A, Morita K, Sakata M, et al. Influence of the PNPLA3 rs738409 polymorphism on non-alcoholic fatty liver disease and renal function among normal weight subjects. PLoS One 2015;10: e0132640. doi: 10.1371/journal.pone.0132640.
78. Nishioji K, Mochizuki N, Kobayashi M, Kamaguchi M, Sumida Y, Nishimura T, et al. The Impact of PNPLA3 rs738409 genetic polymorphism and weight gain $ 10 kg after age 20 on non-alcoholic fatty liver disease in non-obese Japanese individuals. PLoS One 2015;10:e0140427. doi: 10.1371/journal. pone.0140427.
79. Tai CM, Huang CK, Tu HP, Hwang JC, Chang CY, Yu ML. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease. Surg Obes Relat Dis 2015;11:888–894. doi: 10.1016/j.soard.2014.07.016.
80. Tai CM, Huang CK, Tu HP, Hwang JC, Yeh ML, Huang CF, et al. Interactions of a PPARGC1A Variant and a PNPLA3 variant affect nonalcoholic steatohepatitis in severely obese Taiwanese patients. Medicine (Baltimore) 2016;95:e3120. doi: 10.1097/MD.0000000000003120.
81. Honda Y, Yoneda M, Kessoku T, Ogawa Y, Tomeno W, Imajo K, et al. The characteristics of non-obese NAFLD: Effect of genetic and environmental factors. Hepatol Res 2016. doi: 10.1111/hepr.12648.